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Abstract: 
The steroid hormone ecdysone initiates molting and metamorphosis in Drosophila via a heterodimeric receptor 
consisting of EcR that binds hormone, and USP, a homolog of the vertebrate RXR receptor. EcR exists in three 
isoforms EcRA, EcRB1 and EcRB2 that are thought to direct specific physiological responses to ecdysone. 
These three isoforms differ only in their N-terminal A/B domain that implies that sequences responsible for the 
differential physiological effects lie within the A/B domains of the EcR isoforms. In the present study, we set 
out to determine the capability of the three isoforms and their A/B domains to control gene transcription. When 
full-length EcR plasmids were cotransfected into mammalian cells with a USP expressing and a cognate 
reporter plasmid, the three EcR isoforms showed striking differences in their ability to control gene 
transcription, both in the presence and in the absence of hormone. Furthermore, the A/B domains of EcRB1 and 
of EcRB2 when fused to the GAL4 DNA binding domain are sufficient to activate transcription of a reporter 
gene, in yeast as well as in mammalian cells. In contrast, a fusion construct containing the A/B domain of EcRA 
represses basal transcription of the reporter gene. All these findings emphasize the importance of the A/B 
domains of the three EcR isoforms for differentiallly controlling gene transcription. Furthermore, they provide 
evidence for the existence of an autonomous ligand-independent activation function (AF1) in the A/B domains 
of EcRB1 and EcRB2 and of an inhibitory function (IF) in the A/B domain of EcRA. 
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Abstract: 
In Drosophila melanogaster, the steroid hormone 20-hydroxyecdysone (referred to here as ecdysone) is 
responsible for the complete reorganization of the body plan at the end of larval life that characterizes 
metamorphosis. At that time, several pulses of ecdysone activate a genetic cascade that leads to the destruction 
of larval tissues and their replacement by adult tissues and structures (reviewed in [1]). 
 
The biological activity of ecdysone is mediated by a heterodimer of two members of the nuclear receptor 
superfamily: the ecdysone receptor, EcR [2] and Ultraspiracle (USP), a homolog of the vertebrate RXR 
receptors [3-5]. EcR exists in three isoforms, EcRA, EcRB1 and EcRB2, each being able to form heterodimers 
with USP [6-9]. Existence of three ecdysone receptor isoforms may explain partially how a single hormone 
drives such a variety of tissue- and stage-specific responses. Indeed, it has been shown that expression of these 
three EcR isoforms is differentially regulated according to the developmental fate of larval and adult structures 
[6,10,11]. Genetic analyses using isoform specific mutations have provided more direct evidence that EcR 
isoforms are functionally distinct [12,13]. However, the molecular basis for the distinct physiological roles of 
EcR isoforms is not yet understood. The three EcR isoforms contain a common 652 amino-acid C-terminal part 
that includes the DNA binding domain (C domain) and the ligand-binding domain (LBD or E domain). They 
differ only in their N-terminal A/B domains suggesting that the amino-terminal region plays a crucial role in 
mediating the isoform-specific response to hormonal stimuli. 
 
Numerous studies with vertebrate systems have shown that nuclear receptors generally stimulate transcription 
by means of two activation functions (AFs), AF1 located in the N-terminal A/B domain and AF2 located in the 
ligand-binding (D) domain. AF1 is ligand-independent in its transactivation properties while AF2 depends on 
hormone binding. Nevertheless, there is growing evidence indicating that these two independent AFs 
communicate via direct or indirect interactions leading to modulation of the overall transcriptional activity of a 
receptor [14-17]. Although there are several reports on the functional importance of specific binding by EcR 
and USP C domains to cognate ecdysone response elements (EcREs) [8,9,18], very little is known about their 
transactivating domains. We initiated studies to test the hypothesis that it is the A/B domain which determines 
the transactivation specificity of a given EcR isoform. In the present study, we demonstrate that the EcRA, 
EcRB1 and EcRB2 N-termini have distinct transcription controlling capacities. We also present evidence that 
each N-terminal A/B region of the EcRB isoforms exhibits an autonomous activation function, while that of 
EcRA appears to be repressive. 
 
EXPERIMENTAL PROCEDURES  
Plasmid construction 
The DNA sequences coding for the various EcR and USP constructs were amplified using Pfu DNA polymerase 
(Stratagene). EcRA, EcRB1 and EcRB2 fragments were generated by PCR from the plasmids pWT57, pMK1 
and pWT56, respectively. For EcRA, the reverse primer DEr (5'-ACCTCTCTAGACTATG-
CAGTCGTCGAGTGGTC) was combined with the forward primer DEAf (5'CACCCGGATCCACCAT-
GTTGACGACGAGTGGACAA), while for EcRB1 and for EcRB2, DEr was combined with DEB 1f (5'CACC-
CGGATCCACCATGAAGCGGCGCTGGTCGA-AC) or DEB2f (5'CACCCGGATCCACCATGGATACT-
TGTGGATTAGTA), respectively. The underlined nucleotides show BamHI, EcoRI and XbaI cloning sites. 
The boldface letters indicate the Kozak sequence placed adjacent to the start codon ATG for optimal translation. 
The expression plasmid encoding an A/B truncated EcRB1 (252-878) was constructed using the forward primer 
DE-f (5'CACCCGGATCCACCATGA-AGAAGGGACCTGCGC-CA) and the reverse primer DEr. The 
expression plasmid encoding USP was constructed as follows: the cDNA for the Drosophila USP was 
generated using the forward primer DUf (TACCCGAATTCCACCATGGACAACTGCGACCAGGAC) and the 
reverse primer DUr (ACCTCTCTAGACTACTCCAGTTTCATCGCCAG). These fragments were digested 
with BamHI and XbaI (EcR constructs) or EcoRI and XbaI (USP) and cloned in the pcDNA3 vector 
(Invitrogen). 
 
The pPAL1CAT reporter plasmid contains four copies of a synthetic EcRE (PAL1) upstream of the Drosophila 
melanogaster hsp70 promoter sequence (-50 to +200), in front of the CAT reporter gene [19]. 
 
All GAL4-derived expression plasmids for yeast cells are based on the pGBT9 expression vector (Clontech). 
pGBT9-EcRA(A/B), pGBT9-EcRB1(A/B), and pGBT9-EcRB2(A/B) were made by inserting PCR-amplified 
fragments coding for EcRA amino acids 1-234, EcRB1 amino acids 1-263 and EcRB2 amino acids 1-54, into 
BamHI/SalI, BamHI/PstI and BamHI/PstI sites, respectively. 
 
The pGBT9-EcRB1(A/B) deletion mutants were generated by insertion of the corresponding PCR-amplified 
fragment into BamHI/PstI sites of the pGBT9 vector. All restriction sites were in frame with the template, 
ensuring an open reading frame from GAL4 through the entire PCR fragment. 
 
The GAL4 expression plasmids for mammalian cells were derived from the pSCTEV-GAL4 plasmid containing 
the DNA-binding domain of GAL4 (residues 1-93) [20]. Briefly, the various BamHI/PstI EcR fragments were 
excised from the pGBT9 based constructs, blunted at the BamHI site, and cloned into the pSCTEV-GAL4 
vector which had been blunted at the Asp718 sites and then cut at the Pst I site. The pG5E1bCAT reporter 
construct which contains five tandemly repeated GAL4 response elements has already been described [21]. All 
constructs were verified by sequencing. 
 
 
Cell culture, transfection, and reporter gene assay 
HeLa cells were maintained in Dulbecco's modified Eagle's medium supplemented with L-glutamine, 10% fetal 
bovine serum, and 100 U·mL
-1
 penicillin/streptomycin. For transient transfections HeLa cells were seeded in 
10-cm dishes to give 60 - 80% confluence, and after growth for 6 h the cells were transfected by the standard 
calcium phosphate co-precipitation technique [22], using 3 μg of each expression plasmid, 5 μg of reporter 
plasmid (pG5E1b-CAT), 5 μg of plasmid pCH110 (Pharmacia) for transfection control, and calf thymus DNA 
to maintain a total of 20 μg DNA per plate. After 16 h, cells were washed with NaCl/Pi, and fresh medium 
containing muristerone A (Sigma) at 1 mm or solvent control (ethanol) was added. Cells were harvested 40 h 
after transfection, and CAT activity was assayed at 37 °C with 10-μg aliquots of total protein extract. The 
reaction period was varied between 1 and 6 h in order to optimize the production of monoacetylated 
[
14
C]chloramphenicol. Substrate and acetylated products were separated by thin-layer chromatography, and the 
percentage conversion of [
14
C]chloramphenicol to the acetylated forms was quantitated using a Molecular 
Dynamics PhosphorImager. CAT activity of each fusion protein was calculated by normalizing the percent 
conversion per unit reaction time, and it was standardized by division with control plasmid-derived β-
galactosidase activity to yield `relative CAT activity'. Integrity, level of expression and GAL4 response element 
binding capacity of expressed fusion proteins were confirmed by an electrophoretic mobility shift assay using 
aliquots of the nuclear extracts (see below). 
 
Yeast transformation and β-galactosidase assay 
Yeast strain Y187, which has an integrated LacZ gene downstream of GAL4 binding sites, was transformed by 
the poly(ethylene glycol)/LiAc method [23] with pGBT9-based constructs (Clontech). Transformants were 
grown in selective medium, disrupted by three freeze/ thaw cycles and P-galactosidase activity was measured 
using 2-nitrophenyl β-D-galactopyranoside as substrate as specified by the manufacturer. All assays were 
performed in triplicates and repeated at least three times. 
 
Electrophoretic mobility shift assays (EMSAs) 
EcR[ΔA/B], EcRA, EcRB1 and EcRB2 were expressed in vitro using a reticulocyte lysate system as 
recommended by the supplier (TNT T7 Quick coupled Transcription/Translation kit, Promega). The probes 
used correspond to the double-stranded oligonucleotides PAL1/A and hsp27, a synthetic and a natural EcRE 
element, respectively [19]. For the binding reaction, 2 μL of programmed reticulocyte lysate or 6 μg of nuclear 
extract were preincubated for 15 min on ice in a buffer containing 20 mM Hepes/KOH (pH 7.4), 100 mM KCl, 
5% glycerol, 2 mM dithiothreitol, 0.1% NP-40, 50 μg·mL
-1
 poly(dI-dC) in a total volume of 20 μL; muristerone 
A at a final concentration of 10 mM was included in the binding reaction mixture as indicated in the text. 
Approximately 1 ng (30 000 c.p.m.) of an end-filled probe was added to the binding reaction and further 
incubated at room temperature for 20 min. The complexes were separated on a 4% native polyacrylamide gel in 
0.5 x Tris/borate/EDTA. 
 
Nuclear extract from HeLa cells was prepared according to previous reports [24]. Five microliters of this extract 
were incubated for 15 min on ice with 20 μL binding buffer (50 mM KCl, 5 mM MgCl2, 20 mM Hepes (pH 
7.4), 20 μM ZnCl2, 200 mg·mL
-1
 bovine serum albumin, 0.2 M spermidine, 5% glycerol, 100 μg·mL
-1
 
poly(dI~dC), 75 μg·mL
-1
 salmon sperm (DNA). Double-stranded GAL4 response element DNA (made of the 
oligonucleotides 5'-GATCGCACAGTGCCGGAGGACAGTCCTCCGGTTCGAT and 5'-GATCATCGAAC-
CGGAGGACTGTCCTCCGGCACTGTGC-3') was end-labeled by fill-in reaction with [α- 
32
P]dCTP to a 
specific activity of ≈ 10
7
 c.p.m.·μg
-1
, and it was added to the reaction. 
 
 
 
Immunobloting 
Equimolar expression of pcDNA3-based constructs was confirmed after in vitro transcription/translation 
(Promega) by Western blot analysis. Reaction mix (2 μL) was loaded onto a 10% SDS gel. After 
electrophoresis, proteins were transferred onto a nitrocellulose membrane (Schleicher & Schuell) and 
subsequently incubated with the monoclonal antibody DDA2.7 [2] directed against EcR, and AB 11 [25] 
against USP. HeLa nuclear extracts (20 μg) from transcient transfection experiments were used in Western blot 
analyses conducted as described above. The blots were washed and developed by enhanced chemiluminescence. 
 
RESULTS 
DNA binding analysis of EcR isoforms 
As the N-termini were shown to influence the DNA-binding properties of several nuclear receptors [26-28], we 
wanted to assess the DNA-binding capacity of the EcR isoforms and the truncated EcR (EcR[ΔA/B]), by 
utilizing an in vitro system (Fig. 1A). EMSAs were performed with labeled double-stranded oligonucleotides 
corresponding to ecdysone response elements (EcREs). One is a natural element of the Drosophila hsp27 gene 
[29], and the other is PAL1, the most potent EcRE, consisting of an idealized perfect palindrome with a single 
A/T base pair spacing [19]. In vitro translated EcR[ΔA/B], EcRA, EcRB1 or EcRB2 were combined with USP, 
and muristerone A was added to enhance dimerization and DNA binding. All proteins were expressed at similar 
levels (Fig. 1B). As shown in Fig. 1C, all EcR isoforms as well as the truncated receptor exhibited a similar 
DNA-binding affinity. Under the given experimental conditions therefore the A/B region does not seem to 
differentially influence DNA binding of EcR isoforms and thereby the outcome of CAT activity assays. 
 
Differential transcription control capabilities of EcR isoforms 
To compare the transcriptional activity of the EcR isoforms, various EcR expression constructs were transiently 
transfected into HeLa cells along with an USP expression vector and pPAL1CAT which contains four copies of 
the synthetic EcRE PAL1. It has been shown previously that in addition to exhibiting maximal DNA-binding 
activity, PAL1 mediates the highest level of ligand-induced transactivation when compared to other EcREs 
[19]. This is potentially important because EcR is generally regarded a poor transactivator in mammalian cells 
[9,18,30]. Western blot analyses using DDA2.7 and AB11 antibodies against the EcR C domain and the USP D 
domain, respectively, revealed similar levels of expressed EcR forms and USP in all experiments (data not 
shown). 
 
 
 
Figure 1D shows the results of CAT assays performed using cell extracts from transfected HeLa cells. In this 
assay all EcR isoforms as well as the truncated receptor transactivated an EcRE-driven reporter gene in 
response to the ecdysone agonist muristerone A. However, there were significant differences between the 
transactivation potential of the EcR isoforms. EcR[AA/B] and EcRA have quite similar ligand-induced 
transcriptional activities suggesting that the A/B domain of EcRA does not contribute to its transcriptional 
activity. As a matter of fact, the basal activity of unliganded EcRA was even lower than that of EcR[AA/B]. 
With EcRB isoforms we could not detect any repressive effect, either in the absence or presence of ligand. In 
fact, both EcRB1 and B2 showed an enhanced transcriptional activity when compared to the truncated EcR. It is 
interesting to note that EcRB1 and EcRB2 show nearly the same activation potentials, despite profound 
structural differences in their A/B domains, EcRB1 being just slightly more potent than EcRB2.  
 
 
 
Autonomous transcription control functions in the A/B domains of EcRA, EcRB1 and EcRB2 
The fact that EcR isoforms deviate from each other in their capability to control transcription suggests that their 
A/B domains contain different transcription control regions which either act autonomously or in conjunction 
with the ligand-dependent activation function (AF2) thought to be located in the E domain. To investigate these 
possibilities, sequences encoding the A/B domain of the three EcR isoforms were cloned into the yeast 
expression vector pGBT9 to produce fusion proteins consisting of the respective A/B domain and the DNA 
binding domain (DBD) of GAL4. These constructs were transformed into the yeast strain Y187. As shown in 
Fig. 2, the empty plasmid carrying only the GAL4 DBD failed to induce P-galactosidase. Fusion of the A/B 
domain of EcRA to the GAL4 DBD did not stimulate transcription. By contrast, fusion of A/B domains of 
either EcRB1 or EcRB2 resulted in a strong stimulation of the reporter gene. The EcRB1 construct was about 
three times more efficient than the EcRB2 construct. These results indicate the presence of an 
autonomous activation function within the A/B domain of the EcRB isoforms. 
 
To further characterize the activation potential of the various EcR A/B regions and to rule out the possibility 
that this phenomenon is restricted to yeast cells, we examined the transcriptional activity of the fusion proteins 
in HeLa cells containing no endogenous EcR. In this system we used the mammalian expression vector 
pSCTEV-GAL4 [20], and the constructs were cotransfected with the reporter plasmid pG5E1bCAT and with 
plasmid pCH110 for normalization of the CAT values. Correct expression and specific binding to the GAL4 
response element were checked by EMSA using nuclear extract from transfected HeLa cells and a probe 
containing the GAL4 elements (data not shown). 
 
The results obtained with the fusion proteins transfected into HeLa cells are shown in Fig. 3. As demonstrated 
with yeast cells, empty expression vector and the construct carrying the A/B domain of EcRA failed to induce 
reporter activity. Using longer incubation periods we were able to assess and to compare the transactivation 
potential of the empty plasmid and the EcRA[A/B] construct in the absence of ligand more precisely (Fig. 3B). 
Interestingly, the A/B domain of EcRA not only failed to activate transcription but actually repressed the basal 
transcription of the reporter gene as measured with the empty plamid. This repression of basal transcription was 
low but statistically significant (see Fig. 3B); it was consistently observed in nine independent experiments, 
each using a different plasmid preparation. This result indicates that the A/B domain of EcRA contains an 
autonomous inhibitory function. By EMSA we could rule out the alternative possibilities that the fusion protein 
with EcRA[A/B] would exhibit a reduced expression and/ or DNA binding ability compared to the fusion 
protein with EcRB1[A/B]. 
 
 
 
 
Similar to the experiments performed in yeast cells, fusion proteins containing an A/B domain of the B isoforms 
stimulated transcription, particularly when using EcRB 1 [A/B]. In contrast to the results obtained in yeast, a 
rather weak transcriptional activation was observed with EcRB2[A/B]. While these constructs contain only a 
portion of GAL4 DBD (94-147), they do not explain the low activity level of the EcRB2-GAL4 construct, 
because GAL4 constructs containing the entire GAL4 DBD gave similar results. 
 
Mapping of the putative transactivation function (A~1) in the A/B domain of EcRB1 
We wanted to determine the residues that are crucial for transcriptional activation in the A/B domain of the B1 
isoform of Drosophila EcR. This isoform is not only the longest but also the most ubiquitous in insect species. 
Its A/B domain is usually highly variable among EcR proteins from different insects, although some subregions 
are conserved. A sequence alignment (see Fig. 4) with Drosophila melanogaster [2], Aedes ageypti [3 1], 
Manduca sexta [32], and Bombyx mori [33] shows that residues 1 – 53 and residues 214 – 263 are conserved 
whereas the intervening region is highly variable in length and amino-acid sequence. We therefore explored the 
possibility that one or the other of the two conserved regions contains the postulated AF1. We generated a series 
of deletion mutants in the A/B domain, fused them to the GAL4 DBD, and analyzed them for transcriptional 
activity in yeast and HeLa cells. 
 
In yeast cells, truncation of the conserved amino-acid sequence 1 – 53 resulted in a complete loss of 
transcriptional activity suggesting that these amino acids are essential for transactivation (Fig. 5, line 3). 
Surprisingly, deletion of the conserved amino-acid sequence 215 – 263 resulted in a strong increase rather than 
a loss of transcriptional activity, revealing a possible inhibitory function in this stretch of amino acids (Fig. 5, 
line 4). Removal of residues 193 – 214 abolished this enhancement, and the remaining fragment exhibited 
almost the same activity as the full-length A/B domain (Fig. 5, lines 5 and 6). This points to the presence of a 
second transactivation focus in the short stretch of amino acids 193 – 214. However, this function appears to 
depend on amino-acid context as fusion of fragment 141 – 214 to sequence 1 – 53 resulted in only a small 
increase of transcriptional acivity compared to the activation observed with 1 – 53 alone (cf. Figure 5, line 11 
with line 10). Extension of the C-terminal deletions generally caused a progressive reduction of the 
transcriptional activitation potential except for a construct that deleted region 114 – 140, suggesting the 
presence of another, weaker repressive function in the EcRB1 A/B domain (Fig. 5, line 7-10). The construct 
which contained only the conserved N-terminal amino acids stretch 1 – 53 exhibited a weak but significant 
activity (Fig. 5, line 10). 
 
When tested in HeLa cells (Fig. 6) these mutant constructs yielded essentially the same results as the ones 
obtained with yeast. Removal of the conserved N-terminal amino acids 1-53 caused a substantial but incomplete 
loss of activity while deletion of the conserved C-terminal amino acids 215-262 strongly enhanced activity. In 
HeLa cells unlike yeast, the deleterious effect of removing the second activation focus i.e. amino acids 193 – 
214, was so dramatic that possible modulatory functions of intervening amino-acids stretches in region 54 – 192 
could not be studied. Likewise, a construct containing the putative N-terminal activation sequence 1 – 53 alone 
yielded no activity (Fig. 6, line 7). EMSAs performed with extracts from HeLa cells transfected with the various 
constructs showed that in all cases the corresponding fusion proteins were expressed at normal levels (data not 
shown). 
 
DISCUSSION 
The findings presented here show that the three isoforms of the ecdysone receptor of Drosophila not only differ 
qualitatively from each other as suggested by published developmental studies [6,10-13] but also quantitatively 
in terms of transcriptional control of reporter genes in transfected cells. In HeLa cells, the full length proteins, 
when coexpressed with USP, exhibited great differences in the transcriptional control of a CAT reporter gene 
being driven by an EcRE (Fig. 1D). In HeLa cells, as well as yeast cells, fusion proteins containing the A/B 
domain of one of the three isoforms fused to the DNA-binding peptide of GAL4 showed similar differences 
(Figs 2 and 3). In the three experimental regimes described here, the B1 isoform was strongest in transactivation 
whereas the A isoform was inactive or inhibitory. The effect of the B2 A/B domain was less consistent but 
always clearly positive. Dela Cruz and coworkers [34] found a different order of activity when expressing full-
length EcRA, EcRB1 or EcRB2 in yeast cells. However, this order (EcRB1 > EcRA > EcRB2) cannot really be 
compared with that observed by us and others (EcRB1 > EcRB2 > EcRA, see below) because of large 
deviations in the experimental parameters. Thus, we shall focus on the possible relevance of our results to the 
Drosophila system and in vivo situation. 
 
Hu [35] introduced full-length EcRA, EcRB1 or EcRB2 or fusion proteins of their A/B domains with GAL4 
DBD into an EcR-deficient/USP-containing Drosophila cell line by transfection. In both experimental series, 
EcRB1 or its fusion construct was most active in reporter gene activation whereas EcRA or its fusion construct 
was inactive. Salivary glands of larvae, which were mutant in EcRB1, and thus failed to respond to ecdysone by 
target gene activation as revealed by respective puff inductions, could be rescued by transgenic expression of 
EcRB1 or to a lesser degree by EcRB2. However, EcRA did not rescue the response [12]. Recent evidence 
suggests that ectopically expressed EcRA suppresses DHR3 gene activity (M. Schubiger, Department of 
Zoology, Seattle, WA, USA, personal communication). Likewise, ectopic expression of EcRA suppresses 
cuticular tanning in mutant animals (M. Schubiger, personal communication). It generally seems that among 
EcR isoforms, EcRA exhibits the weakest potential to rescue the development of EcR mutant animals (M. 
Schubiger, personal communication; P. Maroy, Department of Genetics, Szeged, Hungary, personal 
communication). In Chironomus tentans an EcR form (cEcR) was found whose A/B domain shares no sequence 
homology with any published EcR [36]. In transient transfection experiments, cEcR is inactive or slightly 
repressive. This repression is attributed to its A/B domain because a replacement of its A/B domain with that of 
Drosophila EcRB1 or with VP16 results in transcriptional activity (V. C. Henrich, M. Lezzi & M. Vögtli, 
unpublished observations). When fused to GAL4 DBD, cEcR[A/B] is inactive (K. Locher and J.-F. Mouillet, 
unpublished observations). Thus, the characterized EcR form of Chironomus functionally resembles Drosophila 
EcRA; inhibitory EcR forms may therefore exist in other insects. A situation in which one isoform is inducing 
transcription whereas another is repressing transcription provides a mechanism for fine tuning transcriptional 
levels, and has been observed for the α and β estrogen receptor isoforms [37,38]. 
 
It will be an interesting and challenging task to unravel the problem of whether and how the described 
quantitative differences are translated into the suggested qualitative differences, evident as tissue- and stage-
specific effects of EcRB1, B2 and A during development. Here, we primarily asked how the activating or 
inhibitory effects of the three isoforms might be brought about. For example, do the A/B domains of the three 
isoforms function autonomously? The fact that any of these A/B domains could be separated from the rest of the 
EcR molecule and be attached to a foreign DNA-binding domain without losing their intrinsic property 
demonstrates that the inhibitory function of EcRA[A/B] and the activating function of EcRB1[A/B] and 
EcRB2[A/B] are largely autonomous. 
 
In contrast to our observations with heterologous host systems, transfection of homologous host cells also 
reveals an inhibitory property of Drosophila EcRB1 and EcRB2 if assayed in the absence of ligand [39]. In fact, 
transferable, thus autonomous, silencing regions have previously been described for Drosophila EcR and shown 
to interact with corepressors like SMRTER and ALIEN [40-42]. However, these regions are located in the C-
terminal part of EcR which is common to all three isoforms. Furthermore, corepressor binding to them is 
sensitive to ligand. They clearly differ from the inhibitory (or silencing) region described in the present paper 
which: (a) is specific for EcR isoform A, (b) is located in the N-terminus, i.e. outside the ligand binding domain, 
and (c) is able to function in the absence of the latter domain. We therefore propose the presence of an isoform-
specific ligand-independent autonomous inhibitory function (IF) in the A/B domain of EcRA, which is able to 
interact with ubiquitous repressor molecules. Existence of an IF in the A/B domain of one of two isoforms has 
been reported for the human progesterone receptor [43,44]. 
 
Regarding the existence and location of autonomous activating functions (AFs) in nuclear hormone receptors, 
the general view is much clearer than with IFs [43]. There exists a ligand-dependent AF (AF2) in the E domain 
with a core motif in helix 12. Additionally there may occur ligand-independent AFs (AF1 and AF3) whose 
locations seem to vary. Most often, AF1 is found in the A/B domain of receptors. It is commonly accepted that 
an AF2 exists also in EcR and that it is located in helix 12 of the E domain [35]. The data presented in this 
paper demonstrate that Drosophila EcRB1 and EcRB2 contain an AF1 which is located in the A/B domain. On 
the basis of sequence comparisons one may assume that the AF1 in the B1 isoform is widespread among 
arthropods (Fig. 4). Moreover, it seems to be ubiquitously active as it functions in yeast as well as in HeLa cells. 
The postulated AF1 of the B2 isoform is probably more specific both in terms of species distribution and tissue-
dependent activity. 
 
Having shown that the A/B domains of EcR isoforms are able to function autonomously does not preclude the 
possibility of their interaction with other domains within the EcR molecule. Seibel [45] showed that binding to 
EcREs is altered by the type of A/B domain present in a given EcR isoform when assayed in the absence of 
USP and ligand. In the presence of USP, though, such an effect of the A/B domain on binding to DNA could 
not be detected (Fig. 1C; [45]). This suggests that under special circumstances there might be intramolecular 
crosstalk between the A/B and the C (DNA binding) domain. Likewise, such a crosstalk must exist between the 
A/B and the E (ligand binding) domain. Muristerone A treatment of transfected HeLa cells switches EcRA from 
a repressive to an active state (Fig. 1D), probably by activating its AF2 in the E domain. A comparison with 
A/B-truncated EcR indicates, however, that this ligand effect is additive rather than cooperative as the ligand-
induced activity is still lower with full-length than with A/B-truncated EcRA (Fig. 1D). This contrasts with the 
situation for EcRB1 and B2 where the effect of ligand is not simply additive but rather synergistic (Fig. 1D) 
indicating for the existence of cooperativity between the putative AF1 located in the A/B domain and the 
putative AF2 in the E domain. Cooperativity between AF1 and AF2 in nuclear receptors is a well known 
phenomenon and is thought to result from binding of multivalent coactivators (e.g. SRC-1, see [15,16,46]) to 
both AFs simultaneously. It will be interesting to identify such cofactors and to map their binding sites in the 
A/B domain of EcR isoforms. 
 
In this study, we discovered an IF and AF1s in the A/B domains of EcRA, EcRB1 and EcRB2, respectively. A 
precise mapping of these functions was attempted only with EcRB1 because the IF in EcRA[A/B] is rather 
weak (HeLa cells) or even undetectable (yeast) while the short A/B domain of EcRB2 leaves little room for 
varying AF1 localization. With the A/B domain of EcRB1, experiments comprising a large series of deletions 
could be performed, both in HeLa as in yeast cells. The results obtained reveal a puzzling pattern of activating 
and inhibitory subregions. Unexpectedly but undoubtedly, the C-terminal region of EcRB1[A/B] (amino acids 
215-263) must harbor a strong inhibitory function as its deletion results in a dramatic increase in the 
transactivation capacity of the respective A/B-GAL4 construct when assayed in either cell type. It remains to be 
shown whether this inhibitory function is autonomous and whether it shares properties with the described IF in 
the A/B domain of EcRA. The dominant AF1 function in EcRB1[A/B] seems to be spread over a large region as 
observed previously [35] with a different series of constructs containing EcRB1[A/B] deletions expressed in 
EcR-deficient Drosophila cells. However, within that region, the activation potential is unevenly distributed. 
Two `hot-spots' are envisaged there, one from amino acid 1 – 53 and another from amino acid 193-214. The 
autonomy of each region does not seem to be very pronounced. In addition, the relative strength of the two 
hotspots appears to vary, maybe in a cell-specific manner. Sequence searches for signature motifs or address 
sites for comodulators did not yield any clear result (not shown). Protein—protein interaction studies will 
probably provide insight into the mechanistic details of the postulated AFs and IFs in the A/B domains of EcR 
isoforms. 
 
In conclusion it may be stated that the A/B domains of EcRB 1 and EcRB2 contain autonomous ligand-
independent activation functions (AF1s) while that of EcRA rather exhibits an autonomous inhibitory function 
(IF). The molecular mode of action of these autonomous functions and their connection to the differential in 
vivo effects of EcR isoforms remains to be elucidated. 
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